S
Steffen Pabel
Researcher at University Hospital Regensburg
Publications - 30
Citations - 591
Steffen Pabel is an academic researcher from University Hospital Regensburg. The author has contributed to research in topics: Medicine & Heart failure. The author has an hindex of 9, co-authored 20 publications receiving 330 citations. Previous affiliations of Steffen Pabel include University of Regensburg & University of Göttingen.
Papers
More filters
Journal ArticleDOI
Empagliflozin directly improves diastolic function in human heart failure
Steffen Pabel,Steffen Pabel,Stefan Wagner,Hannah Bollenberg,Philipp Bengel,Árpád Kovács,Christian Schach,P Tirilomis,Julian Mustroph,André Renner,Jan Gummert,Thomas H. Fischer,Sophie Van Linthout,Carsten Tschöpe,Katrin Streckfuss-Bömeke,Gerd Hasenfuss,Lars S. Maier,Nazha Hamdani,Samuel Sossalla,Samuel Sossalla +19 more
TL;DR: This study aims to investigate whether empagliflozin may cause direct pleiotropic effects on the myocardium, and if so, what mechanisms cause these effects and how they are distributed.
Journal ArticleDOI
Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes.
Julian Mustroph,Olivia Wagemann,Charlotte M. Lücht,Maximilian Trum,Karin P. Hammer,Can Martin Sag,Simon Lebek,Daniel Tarnowski,Jörg Reinders,Filippo Perbellini,Cesare M. Terracciano,Christof Schmid,Simon Schopka,Michael Hilker,York Zausig,Steffen Pabel,Samuel Sossalla,Frank Schweda,Lars S. Maier,Stefan Wagner +19 more
TL;DR: This study tested whether empagliflozin reduces CaMKII‐ activity and improves Ca2+‐handling in human and murine ventricular myocytes and showed reduced mortality and hospitalization due to heart failure in diabetic patients treated with emPaglif lozin.
Journal ArticleDOI
Empagliflozin inhibits Na+/H+ exchanger activity in human atrial cardiomyocytes
Maximilian Trum,Johannes Riechel,Simon Lebek,Steffen Pabel,Samuel Sossalla,Stephan Hirt,Michael Arzt,Lars S. Maier,Stefan Wagner +8 more
TL;DR: This work investigated the effect of empagliflozin on NHE1 activity in human atrial cardiomyocytes and found it to be an inhibition of cardiac Na+/H+ exchanger 1 (NHE1) activity.
Journal ArticleDOI
Antiarrhythmic effects of dantrolene in human diseased cardiomyocytes
Nico Hartmann,Steffen Pabel,Jonas Herting,Felix Schatter,André Renner,Jan Gummert,Hanna Schotola,Bernhard C. Danner,Lars S. Maier,Norbert Frey,Gerd Hasenfuss,Thomas H. Fischer,Samuel Sossalla,Samuel Sossalla +13 more
TL;DR: The study showed that dantrolene beneficially influenced disrupted SR Ca2+ homeostasis in human HF and AF CM, and may be a potential antiarrhythmic drug for patients with rhythm disorders and merits further clinical investigation.
Journal ArticleDOI
Differential regulation of sodium channels as a novel proarrhythmic mechanism in the human failing heart.
Nataliya Dybkova,Shakil Ahmad,Shakil Ahmad,Steffen Pabel,Steffen Pabel,P Tirilomis,Nico Hartmann,Thomas H. Fischer,Philipp Bengel,Theodoros Tirilomis,Senka Ljubojevic,André Renner,Jan Gummert,David Ellenberger,Stefan Wagner,Norbert Frey,Lars S. Maier,Katrin Streckfuss-Bömeke,Gerd Hasenfuss,Samuel Sossalla,Samuel Sossalla +20 more
TL;DR: Involving NaV1.8 inhibition with the specific blockers A-803467 and PF-01247324 decreased INaL, abbreviated APD and reduced cellular-spontaneous Ca2+-release and proarrhythmic events in human failing cardiomyocytes constitutes a promising novel approach for selective anti-arrhythmmic therapy in HF.